Osstem Implants in Turkey What the Data Shows

Most patients meet the name Osstem for the first time on a treatment quote, not in a brochure. That order matters: the question is rarely which brand to want, it is whether the brand already on the quote is acceptable. This page answers that question with verifiable material, and it treats the Korean-origin objection directly rather than talking around it. The system comparison table carries the same specifications side by side for every line we place.

/ Who owns Osstem and where Osstem implants are made

Osstem Implant Co., Ltd. was founded on 7 January 1997 in South Korea and is headquartered in the Magok district of Seoul. Its principal manufacturing site is the K1 plant in Busan, with 19,108 square metres of floor area and a manufacturer-stated annual capacity of 18 million implant sets. The company also manufactures in the United States, China and Brazil, and states total annual production above 22 million sets across those sites.

Ownership changed recently and the question who owns osstem no longer has the same answer it had five years ago. Osstem listed on KOSDAQ in 2007 and was delisted on 14 August 2023 following a buyout. The controlling shareholder today is an investment vehicle formed by MBK Partners and Unison Capital Korea, and Abu Dhabi's Mubadala joined the transaction as an investor in October 2023. Mubadala has not disclosed the size of its stake, and neither has any other primary source, so no percentage is quoted here.

For a patient the practical consequence is narrow but real. A manufacturer with its own legal entities across several markets is easier to reach for components years later than a brand distributed through a single importer. Osstem maintains its own Turkish entity, Osstem İmplant Dış Tic. A.Ş., operating from Istanbul since 2013. That matters for the dental implant treatment you are quoted today only in the long term, when an abutment or a screw has to be replaced.

/ Hiossen is Osstem's own North American arm, not a rival brand

The comparison osstem vs hiossen is one of the most repeated queries around this brand, and the answer circulating on ranking clinic pages is wrong. Several of them frame Hiossen as a separate American brand competing with Osstem. It is not a competitor. Hiossen Inc. was established in 2006 by Osstem, in Pennsylvania, and its own 2025 corporate brochure states plainly that Osstem is its parent company.

The confusion comes from regional naming. In Korea and Europe the fixture families are TS, SS, MS and KS. In North America the same architecture is sold as ET, EM and EK. Surface names diverge too: Europe currently lists SA and SOI, while the hydrophilic surface sold in the United States is branded NH, short for nano-hydrophilic. One manufacturer, two naming systems, and a market that reads them as two brands.

There is one concrete consequence, and it is worth knowing before you fly home. If your follow-up care will happen in the United States, the family written on your implant card as TS will correspond to the ET line locally, and your dentist there will order Hiossen components rather than Osstem-branded ones. Ask for the product code, not only the family name, before you leave the clinic. Our patient journey page explains which documents are handed over at discharge.

/ Is Osstem a good implant: what the published survival data actually shows

Search is osstem a good implant and the top results are forum threads, because almost no clinical source answers the question with numbers. Here are the numbers.

The largest Osstem-specific study is a 2025 retrospective analysis of Osstem TS III SA implants: 2,474 implants in 1,298 patients, all loaded and followed for a minimum of five years and up to ten. Overall survival was 98.3%, peri-implantitis was the leading cause of failure, and in Cox regression the only variable significantly affecting survival was sex (PubMed 41241387). An earlier and much smaller cohort of 467 implants in 105 patients reported a seven-year cumulative survival of 95.37% (PubMed 24868503).

Surface-specific data exists as well. A cohort of 258 calcium-treated CA implants in 120 patients, mean follow-up 62 months, reported 97.3% survival with mean final marginal bone loss of 0.074 mm (PubMed 35351072). A smaller SA-surface cohort of 96 implants in 45 patients reported 94.8% survival (PubMed 32296662).

The honest reading of that range is not "98.3%, therefore excellent." Study populations, implant diameters, sites and follow-up lengths differ, and narrow-diameter subsets sit lower: 3.0 mm TS III implants reported 90.6% survival up to five years (PubMed 37336522). One further finding belongs here for completeness. A single-centre study following 1,162 implants placed between 2001 and 2005 for 12 to 15 years found the highest incidence of peri-implantitis and peri-implant mucositis in the Osstem group among the systems compared (PubMed 34476448). It is published in Chinese, it is single-centre, and the implants studied are two surface generations old, so it does not generalise to the current line. It is stated anyway, because a page that only reports the flattering studies is not a source.

/ Survival and success are not the same measurement

This distinction decides how you should read every brand page you visit, including this one. Survival asks whether the implant is still in the mouth. Success asks a stricter set of questions at once: mobility, pain, radiolucency, bone loss threshold, peri-implant soft tissue condition, prosthetic outcome and patient satisfaction. The systematic review of success criteria in implant dentistry sets these out across four separate levels and shows that most papers report only the first (PubMed 22157097).

The gap is measurable inside a single study. In the Osstem CA cohort, survival was 97.3% while success calculated against Albrektsson criteria was 94.2% (PubMed 35351072). Three percentage points is not a rounding difference; it is the price of asking a harder question.

Every figure on this page is a survival figure, and each one carries the study it came from. If a page quotes you a success rate without naming the criteria used, the number cannot be compared with anything.

/ What Osstem's ranking claim means and what independent trackers say

The query osstem implant market share has proven demand and no sourced answer anywhere. Two different measurements are being mixed.

Osstem's own corporate communication claims the number one position worldwide by unit sales volume and states it held that position for five consecutive years from 2017 to 2021. That is a unit-volume claim from the manufacturer, not a revenue claim, and no methodology is published alongside it.

Independent sources describe a different position. Mubadala's October 2023 investment announcement calls Osstem "the world's fourth largest dental implant material manufacturer." Market research firm iData Research placed Straumann Group, Envista and Dentsply Sirona in the top three in its 2025 assessment, with Osstem grouped among fast-growing global players rather than in that top three. Osstem's own Australian site describes the company as the world's fourth largest.

So the defensible statement is this: Osstem is a top-five global manufacturer; the number one claim applies to unit volume and comes from the manufacturer; independent trackers place it around fourth by revenue and share. An unqualified "world's largest" is not independently verifiable and is not claimed here.

/ The specification sheet: grade 4 titanium, SA surface, 11-degree Morse taper

The Osstem fixture body is commercially pure titanium, grade 4 under ASTM F67, with tensile strength around 550 MPa. Grade 4 is unalloyed. It is frequently confused with grade 5, which is not pure titanium at all but the Ti-6Al-4V alloy containing roughly 6% aluminium and 4% vanadium, with tensile strength between 895 and 1200 MPa. Grouping both under "medical grade titanium" is a common error on brand pages.

The comparison worth drawing is that grade 4 commercially pure titanium is the most widely used fixture material across the field, so it is the shared baseline rather than a differentiator. Where systems genuinely differ is surface treatment and connection geometry, and both are covered below. The material question on the restoration above the implant is separate again, and is set out in our crown material comparison.

The connection in the TS III family is an 11-degree Morse taper combined with an internal hex, a geometry confirmed in the methods section of the 2,474-implant cohort (PubMed 41241387). The taper provides a friction fit; the hex indexes the abutment against rotation. Network meta-analysis of randomised clinical trials found conical interfaces produced less marginal bone loss and fewer prosthetic complications than external hexagonal connections, while showing no significant marginal bone loss difference against internal flat-to-flat connections (PubMed 34776267). Conical is therefore a measured design property with a bounded effect, not a badge.

/ SA, CA, SOI and NH: Osstem's surface families are not interchangeable

SA stands for sandblasted with alumina and acid-etched, exactly as the manufacturer's own TS III SA product document spells it out. Osstem reports the resulting roughness as Ra 2.5 to 3.0 micrometres and states the treatment increases effective surface area by roughly 45%.

A measurement caution belongs with that figure. The "moderately rough" band in the literature is defined as Sa 1.0 to 2.0 micrometres, the range reported to produce the strongest bone response (PubMed 15543910). Ra is a profile measure and Sa is an areal measure; they are not interchangeable and cannot be read directly against each other. The same review adds a caveat rarely quoted by manufacturers: the clinical advantages of moderately rough surfaces over smoother or rougher ones are small and often not statistically significant.

On wettability, the standard SA surface is conventional, not hydrophilic. Osstem's hydrophilic options carry different names. CA is an SA-topography implant stored in calcium chloride solution, which the manufacturer describes as improving hydrophilicity and blood affinity; it is the surface behind the 97.3% survival cohort cited above. The current European catalogue leads with SA and SOI, while NH is the hydrophilic surface sold in the United States through Hiossen. A quote that says only "Osstem" does not tell you which surface you are getting, and the surface is the part with separate published data.

/ What determines the cost of Osstem implant treatment in Turkey

osstem implant cost turkey is the money query for this brand, and the honest version of the answer is a structure rather than a number. No figure is published here, because a price quoted before a CBCT scan describes a product, not your treatment.

Five layers set the total. First, the fixture itself: which family (TS, SS, MS), which diameter and length, which surface (SA, CA, SOI, NH). Second, the number of stages and what is included: a fixture price alone is not a treatment price, because a healing abutment, a final abutment and a restoration follow it. Third, the restoration material, which is a separate line item; the choice between a zirconia crown and other materials moves the total independently of the implant brand. Fourth, additional surgery: insufficient bone volume means grafting, and a low sinus floor in the posterior maxilla means sinus augmentation, neither of which can be predicted without imaging. Fifth, the scale of the case: a single implant, a six-implant arch and a full-arch fixed bridge differ by an order of magnitude in surgical time and laboratory work, and a full-mouth restoration is a different plan again.

Two further points belong in any honest cost discussion. Long-term cost sits outside the quote entirely: component availability, warranty scope and the annual review schedule. And treatment abroad carries travel structure, which is covered on our dental treatment in Turkey page. A written, itemised quote after examination is the only version worth comparing between clinics; book a consultation and ask for it line by line.

/ Warranty, spare parts and who services your implant when you fly home

This is the section most brand pages skip, and it is the one that decides your experience five years from now. Sources contradict each other on Osstem's warranty, so here is what can and cannot be verified.

The only official Osstem warranty document that can be located is published by the UK arm. Its scope is explicit: if an implant fails for any reason it is replaced free of charge, along with any associated abutments, with healing abutments excluded. That is a product replacement guarantee. It does not cover surgical fees or laboratory costs. No global Osstem warranty policy is published, no warranty document exists on the US Hiossen site, and no Turkish-language warranty statement is published either. The frequently repeated "10-year warranty" figure has no manufacturer source at all.

That leaves two distinct warranties that patients routinely merge into one. The manufacturer warranty covers the product. The clinic warranty covers workmanship, reviews and remake if needed. Ask for both in writing, with duration and exclusions stated separately, before treatment starts rather than after; we issue ours at the treatment planning stage.

Component sourcing is the harder problem for a value-tier brand, and it is worth planning for. A general dental practice in the United Kingdom or Germany is less likely to hold Osstem components in stock than the market-leading systems. This is solvable, but only if you leave with the right paperwork. Take the product code, not just the brand name, and confirm which regional line it maps to, since a TS fixture is serviced as an ET component in North America. If you want to compare how other systems handle the same question, the Straumann spec page covers the equivalent ground for that system.

/ Counterfeit risk and how to verify the implant you actually received

Counterfeit and grey-market implants are a real risk category, and the narrative around it is currently written almost entirely by clinics outside Turkey, often naming Osstem and Turkey together. The productive response is not a denial, it is a verification procedure that any patient can run.

European medical device law requires the manufacturer of an implantable device to supply an implant card, and specifies what it must carry: the device name, serial number, lot number, the Unique Device Identification (UDI), the model, and the manufacturer's name and address, together with information on the expected lifetime of the device and any necessary follow-up care (Regulation (EU) 2017/745, Article 18). That card is the artefact that makes a claim checkable.

Three checks follow from it. Confirm that the serial or lot number on your card matches the sticker peeled from the sterile packaging, which is normally affixed to your record at the time of surgery. Confirm that the family and surface written down are a real combination, since SA, CA, SOI and NH belong to specific lines. And confirm the manufacturer name is the legal entity Osstem Implant Co., Ltd. or Hiossen Inc., not a distributor trade name. Any clinic that cannot produce this is a problem regardless of which brand is on the quote; our clinical team issues these documents as standard.

/ Which Osstem lines exist and when each is used

The families are clinical categories rather than price tiers, and the difference determines where each one belongs.

TS is the bone-level tapered main line and carries the bulk of the published evidence, including the 2,474-implant cohort. SS is tissue level, meaning the fixture collar finishes above the bone and the prosthetic connection sits higher. MS is one-piece and designed for narrow ridges, used where bone width is limited and grafting is not the chosen route. KS is a newer bone-level line in the European catalogue. ET, EM and EK are the same architecture under North American branding.

Narrow-diameter implants deserve their own note, because their published numbers sit lower than the standard-diameter figures. MS SA narrow-ridge implants at 2.5 and 3.0 mm reported 95.1% survival at implant level and 96.0% at patient level (PubMed 39743331), while 3.0 mm TS III implants reported 90.6% up to five years (PubMed 37336522). Those figures are not a mark against the line; they reflect that narrow diameters are chosen when anatomy leaves little alternative, and they should be selected with that trade-off stated. Where the ridge can be widened instead, bone grafting keeps a standard diameter on the table.

/ How long Osstem implants last depends more on maintenance than on the brand

how long do osstem implants last invites a number, but the defensible answer is a set of conditions. The largest Osstem cohort reports 98.3% survival at up to ten years, and identifies peri-implantitis as the leading cause of the failures that did occur (PubMed 41241387). The mechanism that ends an implant's life is inflammation in the surrounding tissue, not fatigue in the titanium.

Peri-implant disease is common. The current epidemiology review calculates weighted mean prevalences of 43% for peri-implant mucositis and 22% for peri-implantitis, and its meta-regression shows prevalence rising with function time (PubMed 25495683). The longer an implant is in service, the more the risk accumulates.

Maintenance is the part with measured benefit. A systematic review and meta-analysis of maintenance therapy found lower incidence of peri-implant disease among implants enrolled in supportive programmes and concluded that a recall interval of at least five to six months is warranted (PubMed 26701350). The same analysis identified a history of periodontal disease as a significant influence, which is why gum health is settled before implant planning rather than after.

Brand choice shapes the first day. Maintenance shapes the tenth year. That holds for Osstem and for every other system in our system comparison table, including Neodent, Ankylos, Astra Tech and Medentika.

/ Is Osstem implant safe: the regulatory record

is osstem implant safe is usually asked as a question about country of origin. It is answerable as a question about regulatory records, which are public.

In the United States, Osstem products reach the market through the FDA 510(k) pathway. Verified examples include K161604 for the Osstem Implant System, cleared substantially equivalent on 17 October 2016, and K080594 for the MS System on 3 September 2008. The North American arm files under its own name, for example K183242 covering ET IV SA implants, cleared 21 May 2019. One correction worth carrying: there is no 510(k) titled TS III SA, so a claim of FDA clearance under that exact name is inaccurate; the US equivalents are the Hiossen ET clearances.

In Europe, Osstem received MDR certification covering 4,695 products on 8 January 2026, including class IIb implantable devices, issued by notified body TÜV Rheinland LGA Products, NB 0197, under certificate HZ 2292034-1. The quality management system is registered with TÜV Rheinland under EN ISO 13485 with MDSAP scope. In Korea, the Busan K1 plant received KGMP recertification from the Ministry of Food and Drug Safety in March 2026.

None of this says a Korean system outperforms a Swiss or Swedish one, and no such claim is made here. It says that origin is not the measurable variable. The measurable variables are manufacturing audit status, regulatory clearance and published clinical outcome, and on all three Osstem has a documented record you can check yourself. The same three questions are worth asking of every system on the implant treatment page, and our clinicians will walk through them with you.